Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA4 | P22748 | 5/20 | 0.39 |
| ▸ | CA6 | P23280 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11830328 | 0.98 | KDM4E (0.45) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL3964726 | 0.89 | KDM4E (0.42) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL1363870 | 0.81 | KDM4E (0.44) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL6100726 | 0.80 | CA1 (0.41) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL10793844 | 0.78 | CA1 (0.42) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL11669057 | 0.77 | KDM4E (0.50) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL11058566 | 0.77 | KDM4E (0.50) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL23163117 | 0.75 | KDM4E (0.49) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL25259222 | 0.74 | FAAH (0.41) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL23925244 | 0.74 | FAAH (0.41) | KDM4ENPC1RAB9AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491828-B2 | Liquid phase process for the synthesis of annulated pyridines over molecular sieve catalysts | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2009-02-17 | — | — | US | disclosed |
| US-20060149068-A1 | Liquid phase process for the synthesis of annulated pyridines over molecular sieve catalysts | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149068-A1 | Liquid phase process for the synthesis of annulated pyridines over molecular sieve catalysts | AURKA, CDK4, SKP2 | KDM4E 526/4885NPC1 4339/4885RAB9A 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.